Junko Tanizaki

机构：Kindai University Sakai Hospital, Kindai University · ORCID：0000-0002-6727-9435

发表论文 262 篇 · 总被引 3890 次 · h-index 30

代表论文

TROPION-Lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients with EGFR -mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib (2025 · Therapeutic Advances in Medical Oncology · 被引 7)
Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M) (2026 · European Journal of Cancer · 被引 1)
Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report (2026 · BMC Pulmonary Medicine · 被引 1)
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR -mutated locally advanced or metastatic non-small cell lung cancer (2026 · Therapeutic Advances in Medical Oncology)
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancer (2026 · Lung Cancer)
Abstract 2974: The anticancer effect of TROP2-targeted antibody-drug conjugates (ADC) is potentially attenuated by dysregulated cholesterol metabolism in cancer cells. (2026 · Cancer Research)